Aromatase Inhibitor–Related Musculoskeletal Symptoms: Is Preventing Osteoporosis the Key to Eliminating These Symptoms?

This publication has 29 references indexed in Scilit:

• Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
  Breast Cancer Research, 2007
• Aromatase Inhibitors and Bone Health in Women With Breast Cancer
  Journal of Clinical Oncology, 2006
• Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging
  Breast Cancer Research and Treatment, 2006
• A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
  New England Journal of Medicine, 2005
• Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
  JNCI Journal of the National Cancer Institute, 2005
• Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation
  Arthritis & Rheumatism, 2005
• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
  The Lancet, 2005
• Mutations in the Synthesis and Action of Estrogen: The Critical Role in the Male of Estrogen on Pubertal Growth, Skeletal Maturation, and Bone Mass
  Annals of the New York Academy of Sciences, 2004
• Effects of the Steroidal Aromatase Inhibitor Exemestane and the Nonsteroidal Aromatase Inhibitor Letrozole on Bone and Lipid Metabolism in Ovariectomized Rats
  Clinical Cancer Research, 2004
• A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
  New England Journal of Medicine, 2004